Scholarlink

Background <p>Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of the digestive tract. Mucositis and IBD/colitis are characterized by weight loss and intestinal inflammation. Previous animal studies suggest that the cannabinoid, ∆9-tetrahydrocannabinol (THC), attenuates intestinal inflammation. We aimed to investigate the effect of THC oil on doxorubicin-induced gastrointestinal mucositis and dextran sodium sulphate (DSS) induced colitis in mice.</p> Methods <p>Wild-type C57BL6 mice were used for the experiments. The mice received a daily dose of THC oil at either 10&#xa0;mg/kg or 20&#xa0;mg/kg or vehicle by oral gavage. Mucositis was induced by intraperitoneal injection of doxorubicin, while colitis was induced by supplementing the drinking water with 2% DSS. Gastrointestinal toxicity was evaluated by weight, intestinal lengths, histopathological evaluation, and expression of genes related to chemotherapy-induced mucositis and intestinal inflammation.</p> Results <p>Treatment with THC significantly reduced weight loss and increased the length of the small intestine in the doxorubicin-treated mice. No effects on gene expression of pro-inflammatory cytokines were observed. No effect of THC was observed in DSS-induced colitis.</p> Conclusions <p>THC reduced doxorubicin-induced weight loss, possibly due to increased appetite, but did not affect doxorubicin-induced intestinal inflammation or DSS-induced colitis in mice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delta-9-Tetrahydrocannabinol alleviates doxorubicin-induced weight loss but does not affect dextran sodium sulphate-induced colitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月14日

查看全文
  • Malene Wiborg Johansen,
  • Maria C. E. Andersen,
  • Thomas Nissen,
  • Anders B. Nexoe,
  • Seyda Ünsal,
  • Gunvor I. Madsen,
  • Sören Möller,
  • Jens Kjeldsen,
  • Grith Lykke Sorensen,
  • Uffe Holmskov,
  • Steffen Husby,
  • Mathias Rathe

摘要

Background

Gastrointestinal mucositis is a common adverse effect of chemotherapy. Inflammatory bowel diseases (IBD) are a spectrum of chronic inflammatory disorders of the digestive tract. Mucositis and IBD/colitis are characterized by weight loss and intestinal inflammation. Previous animal studies suggest that the cannabinoid, ∆9-tetrahydrocannabinol (THC), attenuates intestinal inflammation. We aimed to investigate the effect of THC oil on doxorubicin-induced gastrointestinal mucositis and dextran sodium sulphate (DSS) induced colitis in mice.

Methods

Wild-type C57BL6 mice were used for the experiments. The mice received a daily dose of THC oil at either 10 mg/kg or 20 mg/kg or vehicle by oral gavage. Mucositis was induced by intraperitoneal injection of doxorubicin, while colitis was induced by supplementing the drinking water with 2% DSS. Gastrointestinal toxicity was evaluated by weight, intestinal lengths, histopathological evaluation, and expression of genes related to chemotherapy-induced mucositis and intestinal inflammation.

Results

Treatment with THC significantly reduced weight loss and increased the length of the small intestine in the doxorubicin-treated mice. No effects on gene expression of pro-inflammatory cytokines were observed. No effect of THC was observed in DSS-induced colitis.

Conclusions

THC reduced doxorubicin-induced weight loss, possibly due to increased appetite, but did not affect doxorubicin-induced intestinal inflammation or DSS-induced colitis in mice.